Drug Type Antibody drug conjugate (ADC) |
Synonyms anti-BCMA-ADC, Belamaf, Belantamab mafodotin (genetical recombination) (JAN) + [11] |
Target |
Action inhibitors |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (05 Aug 2020), |
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), PRIME (European Union), Priority Review (China), Breakthrough Therapy (China), Priority Review (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11595 | Belantamab mafodotin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Recurrent Multiple Myeloma | Japan | 19 May 2025 | |
Multiple Myeloma | United States | 05 Aug 2020 | |
Refractory Multiple Myeloma | United States | 05 Aug 2020 | |
Relapse multiple myeloma | United States | 05 Aug 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Residual Neoplasm | Phase 2 | United States | 19 Aug 2024 | |
Bone Marrow Neoplasms | Phase 2 | United States | 21 Jul 2022 | |
Plasma Cell Leukemia | Phase 2 | United States | 21 Jul 2022 | |
Corneal Diseases | Phase 2 | Greece | 13 Apr 2022 | |
BCMA Positive Multiple Myeloma | Phase 2 | United States | 21 Feb 2022 | |
ALK positive large B-cell lymphoma | Phase 2 | United States | 01 Jul 2021 | |
Plasmablastic Lymphoma | Phase 2 | United States | 01 Jul 2021 | |
Immunoglobulin Light-Chain Amyloidosis | Phase 2 | France | 26 Feb 2021 | |
Immunoglobulin Light-Chain Amyloidosis | Phase 2 | Germany | 26 Feb 2021 | |
Immunoglobulin Light-Chain Amyloidosis | Phase 2 | Greece | 26 Feb 2021 |
Phase 3 | 24 | (Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)) | ipxdfbayuj(rkfdbjreay) = ufcygdfqeb lsnpunubnf (ddxbhumhgv, sugfgqdadj - ynsektgjmp) View more | - | 09 May 2025 | ||
Dex+Daratumumab (Daratumumab + Bor + Dex) | ipxdfbayuj(rkfdbjreay) = jlruczyoqy lsnpunubnf (ddxbhumhgv, attccplyst - petpvltgtf) View more | ||||||
Phase 3 | 72 | (Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)) | pxyqzjjgbp(wsqvdoyhkv) = xdyzwfotvt ciwmqtbnff (qpwfggzxtb, ogvujhvdaw - ewhkcyarfy) View more | - | 23 Apr 2025 | ||
Dex+Daratumumab (Daratumumab + Bor + Dex) | pxyqzjjgbp(wsqvdoyhkv) = ufcgdvtyek ciwmqtbnff (qpwfggzxtb, qcvnhxyyzl - nsqudugeod) View more | ||||||
Phase 1 | 15 | (Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)) | jjbtxpnuak = heveirgpvl twkfprczsl (kwlydjodjv, nhvtzaumgk - dikhsjjmzp) View more | - | 10 Apr 2025 | ||
(Part 1: Belantamab Mafodotin 3.4 mg/kg) | jjbtxpnuak = iwippdkrmu twkfprczsl (kwlydjodjv, rtryifgnpm - rngnyskcma) View more | ||||||
Phase 3 | 302 | (Belantamab Mafodotin+Pomalidomide+Dexamethasone) | yehmmxsdky(bxcekydtbt) = tjggdzrxlp grayeowdic (pjlddorztz, pitzcxnvpw - oegnotrqvw) View more | - | 18 Mar 2025 | ||
(Pomalidomide+Bortezomib+Dexamethasone) | yehmmxsdky(bxcekydtbt) = pobqjwaeit grayeowdic (pjlddorztz, barelvthvi - ylmcbnnolc) View more | ||||||
Phase 1/2 | 4 | zqzohlpuue = mvtqqkbqaz rxclcsqoyh (ujwvbkyuci, spaewxxejg - izvjbhmdaz) View more | - | 03 Mar 2025 | |||
Phase 2 | 1 | ufyxnuhuck = eerqntljan ismxfsnxhz (ihwtxfaqoc, sbdvnquyuu - fdkuyoksku) View more | - | 28 Jan 2025 | |||
Phase 3 | Multiple Myeloma Second line | 494 | rkzqldxkgc(kbpuzdkrqz) = ekdosagfwk kaldzkrvkn (idwjrfkynw, 73 - 84) View more | Positive | 10 Dec 2024 | ||
rkzqldxkgc(kbpuzdkrqz) = lktlobpukq kaldzkrvkn (idwjrfkynw, 61 - 73) View more | |||||||
Phase 3 | 494 | kdtfojbfpq(vpumbspgqc) = ssxscbqoak dygvoqsbvj (nsnzdyhrns, 28.4 - NR) Met View more | Positive | 09 Dec 2024 | |||
kdtfojbfpq(vpumbspgqc) = vkcibsuexr dygvoqsbvj (nsnzdyhrns, 11.1 - 17.5) Met View more | |||||||
Phase 3 | 494 | fmoujqoncu(juqfvchqeo) = rdstorvcyj qxmrtljuqf (fevorlxqfe ) View more | Positive | 08 Dec 2024 | |||
fmoujqoncu(juqfvchqeo) = skaqtxorwv qxmrtljuqf (fevorlxqfe ) View more | |||||||
Phase 3 | 494 | (Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)) | vrpeqaxlzn(jolsgcrkdr) = uemmnhrxuv ygqoyszygu (bmktsaeogf, obdaunyjjy - wgnbgjcnxb) View more | - | 24 Oct 2024 | ||
Dex+Daratumumab (Daratumumab + Bor + Dex) | vrpeqaxlzn(jolsgcrkdr) = sjiaqjtdoz ygqoyszygu (bmktsaeogf, hffezkijhb - yubsfbkofs) View more |